Cyan Reef is an independent publisher and comparison service, not an investment advisor. Its articles, interactive tools and other content are provided to you for free, as self-help tools and for informational purposes only. They are not intended to provide investment advice. Cyan Reef is not compensated by the any third-party for the information published.

APO Medical Opportunities Fund

Provider: IPConcept | Official Instrument Web (external)

Instrument Profile

Short Description

The aim of the investment policy of apo Medical Opportunities is to achieve long-term growth in value in the fund currency, taking into account the investment risk generate.

Investment Strategy

The composition of the portfolio is determined by the fund manager exclusively according to the investment policy defined criteria, regularly checked and adjusted if necessary. The risk of the fund is 50% with the risk of MSCI Daily TR World Net Health Care Equipment & Services Index, 35% MSCI Daily TR World Net Biotechnology Index and 15% MSCI Daily TR World Net Pharmaceuticals Index compound Reference portfolios compared. The investment universe of the fund is not limited to the constituents of the index. he indices can therefore differ significantly from the performance of the fund. The fund invests at least 51% of its assets in equities, equity-like securities and certificates issued in Europe, North, Central and South America, Africa, Asia or Australia. The fund invests at least 60% of the fund’s net assets directly in shares. The fund invests in companies that can benefit from developments in the global healthcare market. The fund can also invest its assets in other funds and bank balances.

Type: FCP
Geography: Broad Developed Markets
Sector: Healthcare - Broad

Ongoing Charges: 1.80% (Estimated)
Initial Charge: 5.00%
Investment Style: Sector Equity Healthcare
Fund Size (AUM): EUR 745.14M

Data by the open sources of the instrument provider. Last update: 3.12.2020

MSCI Sustainability Score


Source: MSCI Inc.
Last update: Dec 3rd, 2020

Morningstar Sustainability Score


Source: Morningstar, Inc.
Last update: Dec 3rd, 2020

Rolling performance at 4/12/2020

1 Year: 17.66%

3 Years: 10.51%

5 Years: 13.56%

Performance data by the open sources of the instrument provider. Last update: 4.12.2020

Top 10 Holdings


Bristol-Myers Squibb Company

Pfizer Inc

Roche Holding AG Dividend

Right Cert.

Merck & Co Inc

Sanofi SA

Centene Corp

UnitedHealth Group Inc

AbbVie Inc

Seagen Inc Ordinary Shares












Top portfolio holdings as of 6.12.2020 | Source: instrument provider.

Interested in this instrument?

Join the community

Subscribe to receive the latest analytics and materials on impact investing.

The information made available to you does not constitute the giving of investment advice or an offer to sell or the solicitation of an offer to buy any security of any enterprise in any jurisdiction. The securities listed above are not registered and will not be registered for sale in the United Sates and cannot be purchased by U.S. investors as the securities can only be purchased in jurisdictions where they have been registered for sale or where an exemption from registration applies. The offer, sale or delivery of the securities within the United States or to, or for the account or benefit of, U.S. Persons is not permitted except pursuant to an exemption from registration under U.S. securities laws, which may not be available; and the availability of the information through the website does not alter or change the persons eligible to purchase the security. All information on this page is subject to Cyan Reef Terms & Conditions. The branding materials of the financial instruments displayed on this web-page are property of the respective instrument providers. Although the information provided was collected with due care, Cyan Reef does not and may not under any circumstances be responsible for the accuracy of the information provided hereby. All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cyan Reef and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.